Columns Ocrevus MS News That Caught My Eye Last Week: Mavenclad, Tecfidera, Ublituximab, Ocrevus MS News That Caught My Eye Last Week: Mavenclad, Tecfidera, Ublituximab, Ocrevus by Ed Tobias | October 23, 2017 Share this article: Share article via email Copy article link The giant ECTRIMS/ACTRIMS MS conference begins in Paris on Wednesday, Oct. 25, and this column focuses on several of the presentations on which Multiple Sclerosis News Today will be reporting during the week. #MSParis2017 ā Mavenclad Reduces Relapses, Prevents New Lesions in Many RRMS Patients, Presentations Will Show This report will be of major interest because Mavenclad was approved for use in the EU Ā this past summer, after being denied approval earlier. The reversal happened after studies showed big-time success treating patients with very active RRMS. Mavenclad reduced multiple sclerosis relapses by 79 percent and prevented the development of additional inflammatory lesions in 84 percent of patients with high disease activity, according to presentations Merck KGaAĀ will make in Paris next week. The company willĀ share a host of new data at theĀ 7th Joint ECTRIMS-ACTRIMS MeetingĀ on Mavenclad (cladrabine tablets), which the European Union recentlyĀ approved for the treatment of relapsing-remitting MS. **** #MSParis2017 ā Alkermes to Give Updates on ALKS 8700 Studies at ECTRIMS-ACTRIMS Meeting This report will be of special interest to patients who use Tecfidera, or have tried it, and have had stomach problems when using it. The researchers testing ALKS 8700 believe that it will provide the benefits of Tecfidera without the intestinal side effects. Alkermes will showcase its work in developing a treatment that harnesses the effect of Tecfidera (dimethyl fumarate) for relapsing multiple sclerosis (MS), while lowering the risk of stomach problems at the 7th Joint ECTRIMS-ACTRIMS Meeting this month in Paris. The investigational drug, ALKS 8700, uses the same mechanism of action as Tecfidera. By building the molecule in a different way, however, the company expects it will show better tolerability. **** #MSParis2017 ā TG Therapeuticsā Ublituximab Depletes Harmful B-cells and Lowers MRI Lesions, Trial Shows Another hopeful report of an investigational drug, this one labeled TG-1101Ā ā¦ halting relapses and reducing brain and spinal cord lesions by attacking specific B-cells. TG TherapeuticsāĀ ublituximab (TG-1101)Ā nearly eradicated a type of immune B-cell believed to be involved in multiple sclerosis,Ā according to a Phase 2 clinical trial. The result was that none of the patients had a relapse during the first six months of the trial (NCT02738775), which is continuing, researchers said. **** #MSParis2017 ā Genentech to Share Host of New Ocrevus Data at ECTRIMS-ACTRIMS Meeting Ocrevus is one of the newer, “hot” MS drugs that’s in use. Since it hasn’t been very long since the FDA approved it for use in the U.S., there’s a lot of interest in these follow-up studies that the drug’s manufacturer, Genentech, will be reporting. There will be 18 studies presented, most of them focusing on Ocrevus’ risk-benefit picture. GenentechĀ will present a host of new information on its multiple sclerosis treatmentĀ Ocrevus (ocrelizumab)Ā and lessons its scientists have learned about the disease at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, Oct. 25ā28. The presentations will offer new insights into the therapyās mechanisms, safety and effectivenessĀ in people with primary progressive and relapsing forms of MS. They will also look at new ways to track MS, including additional biomarker possibilities. *** Note:Ā Multiple Sclerosis News TodayĀ is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those ofĀ Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. Heās also the author of āThe Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.ā Ed and his wife split their time between the Washington, D.C. suburbs and Floridaās Gulf Coast, trying to follow the sun. Tags #MSParis2017, Mavenclad, Ocrevus, Tecfidera Comments Shirley L Waddell I would love to try the drug currently in testing that would remove the horrendous stomach problems I encountered with Tecfidera. I was achieving results from Tecfidera until I just couldn't tolerate the stomach side effects. Sign me up for trials or when the new drug becomes available. Reply Me That drug is Mavenclad. It's already available in the US as generic, off-label injectable cladriibine. I've taken my 2 sets of treatments already. Reply Des What stomach problems are associated with Tech? Reply Gail Alexander I too had to discontinue Tecfidera due to intestinal upset. Looking forward to a new and improved version. I have been on 4 different DMTs with varying side effects. Other than intestinal issues, the Tecfidera seemed to be effective. My insurance wonāt cover Ocrevus. It did cover Tecfidera. Hoping, hoping, hoping. Reply Claudius Mott Why Ocrevus has not yet been used for SPMS?. Rituximab, similar to Ocrelizumab (?)has already been tested for it. Reply BRENDA BLAKE I completed my Ocrevus infusions in late June. I have not seen any improvement, but no nausea only some itching-less than with Techfidera. My next infusion is Dec. 12. I'm praying for no new lesions. Reply Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression